Currently, specific inhibitors against BER proteins such as Polβ, PNKP, FEN1, Ligase IIIα, and PARP1/PARG have been developed either to sensitize several cancers or to form synthetic lethal partnerships with common cancer mutations (reviewed in Grundy and Parsons, 2020). Here, POLB is linked to cancer.